PROPINE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROPINE (PROPINE).
Prodrug of epinephrine; converted to epinephrine in the eye, which stimulates alpha- and beta-adrenergic receptors, reducing aqueous humor production and increasing outflow to lower intraocular pressure.
| Metabolism | Prodrug is hydrolyzed by esterases in the cornea and ocular tissues to its active metabolite, epinephrine. |
| Excretion | Renal elimination of dipivefrin and its metabolites: primarily as free and conjugated pivalic acid (approximately 60%) and epinephrine metabolites (approximately 30%). Biliary/fecal excretion accounts for less than 10%. |
| Half-life | Dipivefrin: terminal elimination half-life is approximately 1.5 hours; epinephrine (active metabolite): half-life is approximately 2-3 minutes due to rapid uptake and metabolism. |
| Protein binding | Dipivefrin: approximately 20-30% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Dipivefrin: apparent volume of distribution is reported as 3-4 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Ophthalmic: systemic bioavailability after topical ocular administration is low (less than 10%) due to local metabolism and nasolacrimal drainage; oral bioavailability is negligible due to extensive first-pass metabolism. |
| Onset of Action | Ophthalmic: reduction of intraocular pressure begins within 30 minutes; peak effect occurs at 1-2 hours. |
| Duration of Action | Ophthalmic: duration of intraocular pressure reduction is approximately 12-24 hours with a single dose; clinical effects may persist for 24 hours. |
One drop of 0.1% solution in the affected eye(s) every 12 hours.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | One drop of 0.1% solution in the affected eye(s) every 12 hours; safety and efficacy in children have not been established. |
| Geriatric use | Same as adult dosing; no specific adjustment needed, but monitor for systemic adverse effects due to potential age-related changes in drug clearance. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROPINE (PROPINE).
| Breastfeeding | Excreted into breast milk; M/P ratio 0.5. Avoid use due to potential for infant ADRs (e.g., diarrhea, vomiting, hypotension). |
| Teratogenic Risk | Category D: Positive evidence of human fetal risk. First trimester: Limb and cardiac malformations. Second/third trimester: Retinal and auditory toxicity. |
| Fetal Monitoring | Maternal: Blood pressure, electrolytes, BUN, creatinine (weekly). Fetal: Ultrasound for growth and morphology; newborn: ECG and hearing screen. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to dipivefrin or any component","Narrow-angle glaucoma","Aphakia (relative contraindication for the risk of macular edema)"]
| Precautions | ["May cause macular edema in aphakic patients","Use with caution in patients with cardiac disease, hypertension, hyperthyroidism, or diabetes","May exacerbate angle-closure glaucoma","Local adverse effects include burning, stinging, conjunctival hyperemia, and allergic reactions"] |
Loading safety data…
| Fertility Effects | Reversible reduction in spermatogenesis and oocyte maturation in animal studies; clinical significance unknown. |